Key Highlights

  • Amaero (ASX:3DA) rose about 7.6% intraday on 21 July 2026.
  • No confirmed company-specific announcement explained the move.
  • FY2026 revenue guidance remained at AUD 18–20 million.
  • The company recently submitted a confidential US IPO filing.

Shares of Amaero Inc. (ASX:3DA) climbed about 7.6% during intraday trading on 21 July 2026, ahead of the company's June-quarter activities report and Appendix 4C due the following day. No company-specific announcement was released on the day to explain the rise, although recent operational developments and the upcoming quarterly update kept the advanced manufacturing company in focus. The move represented an intraday reading rather than a closing price.

Advanced Manufacturing Business Remains the Core Focus

Amaero manufactures spherical titanium and refractory-alloy metal powders used in defence, aerospace and additive manufacturing applications. Operating from Tennessee in the United States, the company supplies domestically produced metal powders for critical US supply chains and is also expanding its powder metallurgy capabilities through PM-HIP component manufacturing.

Recent Progress Supports Growth Strategy

For the March 2026 quarter, Amaero reported revenue of AUD 2.6 million, a 301% increase from a year earlier, while reaffirming FY2026 revenue guidance of AUD 18–20 million. The company ended the quarter with approximately AUD 38.3 million in cash and recently completed a three-year AUD 72 million investment programme in the US. Earlier this month, it also confidentially submitted draft registration documents for a proposed US initial public offering.

What Investors May Watch Next

Investors may monitor the June-quarter report, progress on the proposed US listing, production ramp-up following the resumption of titanium powder manufacturing, customer contract execution and future capacity expansion. Updates on defence-related programmes and new supply agreements may also remain in focus.

Risks

Amaero remains exposed to manufacturing, execution, customer concentration and funding risks. Delays in production, slower conversion of contracted revenue, regulatory hurdles surrounding the proposed US listing and fluctuations in demand from defence and industrial customers could influence future performance.